There’s a lot to be optimistic about in the Healthcare sector as 2 analysts just weighed in on Zoetis (ZTS – Research Report) and MiMedx Group (MDXG – Research Report) with bullish sentiments.
Zoetis (ZTS)
In a report released today, Jonathan Block from Stifel Nicolaus maintained a Buy rating on Zoetis, with a price target of $215.00. The company’s shares closed last Friday at $197.32, close to its 52-week high of $201.92.
According to TipRanks.com, Block is a 5-star analyst with an average return of
The word on The Street in general, suggests a Strong Buy analyst consensus rating for Zoetis with a $232.60 average price target, representing a 18.9% upside. In a report issued on February 9, Barclays also assigned a Buy rating to the stock with a $255.00 price target.
See today’s best-performing stocks on TipRanks >>
MiMedx Group (MDXG)
In a report released today, Carl Byrnes from Northland Securities maintained a Buy rating on MiMedx Group, with a price target of $12.00. The company’s shares closed last Friday at $7.96.
According to TipRanks.com, Byrnes is currently ranked with 0 stars on a 0-5 stars ranking scale, with an average return of
Currently, the analyst consensus on MiMedx Group is a Moderate Buy with an average price target of $12.00.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Read More on ZTS:
